CL
SUPN icon

Choreo LLC’s Supernus Pharmaceuticals SUPN Stock Holding History

Choreo LLC’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$509K Sell
10,936
-475
-4% -$22.8K 0.01% 984
2026
Q1 		$590K Sell
11,411
-46
-0.4% -$2.34K 0.01% 852
2025
Q4 		$572K Buy
+11,457
New +$557K 0.01% 863

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Choreo LLC's SUPN Position: Q2 2026 in Review

Choreo LLC reduced its Supernus Pharmaceuticals (SUPN) stake by 4.2% in Q2 2026, selling an estimated $22.8K and leaving 10,936 shares worth $509K. The position accounts for 0.01% of the portfolio, ranked #984.

Choreo LLC first reported a position in SUPN in Q4 2025 and has held it in 3 quarters since. The position peaked at $590K in Q1 2026. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Choreo LLC held 10,936 shares of Supernus Pharmaceuticals worth $509K as of Q2 2026.
  • Choreo LLC sold 475 Supernus Pharmaceuticals shares in Q2 2026, an estimated $22.8K.
  • Supernus Pharmaceuticals made up 0.01% of Choreo LLC's portfolio in Q2 2026, its #984 holding.
  • Choreo LLC first reported a position in Supernus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Choreo LLC's Supernus Pharmaceuticals position peaked at $590K in Q1 2026.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Choreo LLC's 13F filing for Q2 2026, filed 4 Aug 2026.